At close: 4:00:02 PM EST
After hours: 4:04:45 PM EST
Breakdown
TTM
8/31/2024
8/31/2023
8/31/2022
8/31/2021
Total Revenue
464.2780
464.2780
226.2080
255.3970
722.7380
Cost of Revenue
4.8220
4.8220
31.5000
71.8410
175.3460
Gross Profit
459.4560
459.4560
194.7080
183.5560
547.3920
Operating Expense
6,212.5860
6,212.5860
6,728.7300
6,802.5950
6,234.2440
Operating Income
-5,753.1300
-5,753.1300
-6,534.0220
-6,619.0390
-5,686.8520
Net Non Operating Interest Income Expense
14.3110
14.3110
43.1900
--
--
Other Income Expense
-69.8350
-69.8350
-221.6930
-764.6140
1,522.7040
Pretax Income
-5,808.6540
-5,808.6540
-6,712.5250
-7,383.6530
-4,164.1480
Net Income Common Stockholders
-5,795.3450
-5,795.3450
-6,664.8990
-7,269.3240
-4,027.0060
Diluted NI Available to Com Stockholders
-5,795.3450
-5,795.3450
-6,664.8990
-7,269.3240
-4,027.0060
Basic EPS
-0.47
--
-1.01
-1.24
-0.95
Diluted EPS
-0.47
--
-1.01
-1.24
-0.95
Basic Average Shares
12,383.9740
--
6,614.0660
5,885.2450
4,391.4460
Diluted Average Shares
12,383.9740
--
6,614.0660
5,885.2450
4,391.4460
Total Operating Income as Reported
-5,753.1300
-5,753.1300
-6,534.0220
-6,619.0390
-5,686.8520
Total Expenses
6,217.4080
6,217.4080
6,760.2300
6,874.4360
6,409.5900
Net Income from Continuing & Discontinued Operation
-5,795.3450
-5,795.3450
-6,664.8990
-7,269.3240
-4,027.0060
Normalized Income
-5,725.5100
-5,725.5100
-6,443.2060
-6,504.7100
-5,527.7100
Interest Income
14.3110
14.3110
43.1900
--
--
Net Interest Income
14.3110
14.3110
43.1900
--
--
EBIT
-5,753.1300
-5,753.1300
-6,534.0220
-6,619.0390
-5,686.8520
EBITDA
-5,676.9770
-5,676.9770
-6,388.6250
-6,516.3210
-5,539.2550
Reconciled Cost of Revenue
4.8220
4.8220
31.5000
71.8410
175.3460
Reconciled Depreciation
76.1530
76.1530
145.3970
102.7180
147.5970
Net Income from Continuing Operation Net Minority Interest
-5,795.3450
-5,795.3450
-6,664.8990
-7,269.3240
-4,005.0060
Total Unusual Items Excluding Goodwill
-69.8350
-69.8350
-221.6930
-764.6140
1,522.7040
Total Unusual Items
-69.8350
-69.8350
-221.6930
-764.6140
1,522.7040
Normalized EBITDA
-5,607.1420
-5,607.1420
-6,166.9320
-5,751.7070
-7,061.9590
8/31/2021 - 1/12/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ANL Adlai Nortye Ltd.
1.9880
-0.60%
BCTXW BriaCell Therapeutics Corp.
0.1600
-17.91%
THTX Theratechnologies Inc.
1.8700
-6.27%
EQ Equillium, Inc.
0.7006
-2.21%
KALV KalVista Pharmaceuticals, Inc.
7.85
-4.73%
GYRE Gyre Therapeutics, Inc.
9.99
+3.85%
XLO Xilio Therapeutics, Inc.
1.1000
-1.79%
ORMP Oramed Pharmaceuticals Inc.
2.3900
+0.42%
SLNO Soleno Therapeutics, Inc.
43.11
-3.17%
ANAB AnaptysBio, Inc.
14.21
-1.04%